Substance Use Disorder

Psychedelics, addiction, and recovery

Psychedelic-assisted therapy's history, Bill W's admiration, and the need for peer support group understanding are discussed in relation to sobriety, recovery, and psychedelics.

Kevin Franciotti, Reilly Capps, Celeste Alvarez, Danielle Nova, Rick Barnett, Juliana Mulligan

PS2023 Harm Reduction Policy and Advocacy Psilocybin Psychedelic Assisted Therapy Research Substance Use Disorder

Psilocybin Treatment of Tobacco Addiction: From a Wing and a Prayer to Federally Funded Psychedelic Therapy Research

Psilocybin research journey: investigating its use for treating tobacco addiction. Includes pilot study, comparative efficacy study, and upcoming multi-site clinical trial funded by NIDA.

PS2023 Harm Reduction Psilocybin Psychedelic Assisted Therapy Research Substance Use Disorder

Effects of Psilocybin in Alcohol Use Disorder: Beyond Reduction

Dr. Bogenschutz presents quantitative findings from a psilocybin trial for alcohol use disorder, showing reduced alcohol craving and improved mood and cognition. Dr. Agin-Liebes discusses qualitative results on self-awareness and

Gabrielle Agin-Liebes

PS2023 Ancestral Knowledge Ibogaine Plant Medicine Psychedelic Assisted Therapy Research and Science Substance Use Disorder

A Study of Oral Ibogaine in Opioid Withdrawal and Relapse Prevention

Ibogaine, a transformative psychedelic medicine, shows promise in treating addiction by altering perception and mood. With a long history of use, it is now being tested in clinical trials.

PS2023 Harm Reduction Health Conditions Ketamine Psychedelic Science Research and Science Substance Use Disorder

The Mirror Molecule: How can ketamine and other substances be both addictive and anti-addictive?

Ketamine and psilocybin show promise for health conditions but come with risks, including addiction. This talk challenges the view of drugs as neutral tools and explores their complex nature and

Elias Dakwar

PS2023 Harm Reduction Policy and Advocacy Psychedelic Assisted Therapy Public Benefit Research and Science Substance Use Disorder

Panel discussion and Q&A with addiction researchers

Substance use disorder cases doubled during the pandemic, with over 100,000 drug overdose deaths in 2020. Research explores psychedelic-assisted therapy as a potential paradigm shift in addiction treatment efficacy.

Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks

PS2023 Psychedelic Assisted Therapy Psychedelic Science Psychedelic-AT Research Research and Science Substance Use Disorder

The Impact of Psychedelic Drugs on Brain Function and Cognition

Manoj Doss discusses psychedelic impact on episodic memories, highlighting FLUX theory. Fred Barrett explores psychedelic therapy's potential for lasting shifts in psychological and cognitive flexibility across disorders.

Frederick Barrett, Manoj K. Doss

PS2023 Anxiety Depression Psychedelic Science Research Research and Science Substance Use Disorder

Molecular and neuronal responses to psychedelic-induced plasticity

Psychedelics elevate neural activity, engage neural plasticity, and may relieve depression, anxiety, or addiction symptoms. Research focuses on neuron types and plasticity mechanisms in the prefrontal cortex.

Andrea Gomez

PS2023 Harm Reduction Psilocybin Psychedelic Assisted Therapy Research and Science Substance Use Disorder Therapy Ethics

Effects of psilocybin-assisted psychotherapy on personality and their relationship with self-compassion among individuals with alcohol use disorder

Psilocybin study shows personality changes and increased self-compassion in alcohol use disorder patients. Larger studies needed to confirm impact on AUD outcomes.

Broc A Pagni

PS2023 Harm Reduction Health Conditions Ibogaine Psychedelic Science Research Substance Use Disorder

Preliminary results from a Pilot study of the efficacy and safety of ibogaine in the treatment of methadone detoxification

Study on ibogaine for methadone dependence treatment aims to establish safe detox protocol through first Phase-II trial. Weekly low-dose evaluations conducted to gather safety and efficacy data for future research.

Jose Carlos Bouso